PubRank

Maurizio Brausi

Author PubWeight™ 36.62‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2012 4.08
2 Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 2006 3.39
3 Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 2013 2.84
4 Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009 2.71
5 Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS). BJU Int 2013 1.87
6 Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 2005 1.81
7 Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906). J Urol 2005 1.64
8 Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol 2011 1.62
9 Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. Eur Urol 2008 1.51
10 Morbidity and quality of life in elderly patients receiving ileal conduit or orthotopic neobladder after radical cystectomy for invasive bladder cancer. Urology 2008 1.19
11 The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression. Carcinogenesis 2004 1.18
12 Clusterin (SGP-2, ApoJ) expression is downregulated in low- and high-grade human prostate cancer. Int J Cancer 2004 1.05
13 Metastasis markers in bladder cancer: a review of the literature and clinical considerations. Eur Urol 2004 0.96
14 Role of multiparametric magnetic resonance imaging (MRI) in focal therapy for prostate cancer: a Delphi consensus project. BJU Int 2014 0.93
15 Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation. Virchows Arch 2002 0.86
16 Lymphadenectomy for bladder cancer at the time of radical cystectomy. Eur Urol 2013 0.86
17 Anticancer activity of green tea polyphenols in prostate gland. Oxid Med Cell Longev 2012 0.84
18 European Study of Radical Prostatectomy: time trends in Europe, 1993-2005. BJU Int 2007 0.83
19 Are new technologies for detection and treatment of non-muscle-invasive bladder cancer (NMIBC) so important? A plea for adoption by teaching programs to improve results after standard white light transurethral resection of NMIBC. Eur Urol 2012 0.82
20 Successful prediction of prostate cancer recurrence by gene profiling in combination with clinical data: a 5-year follow-up study. Cancer Res 2003 0.80
21 The future of urology. Eur Urol 2011 0.79
22 Measuring and improving the quality of transurethral resection for bladder tumour (TURBT). BJU Int 2011 0.79
23 Radical cystectomy for BCG failure: has the timing improved in recent years? BJU Int 2011 0.75
24 Editorial comment on: P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Eur Urol 2007 0.75
25 Collateral activity of immunotherapy with bacillus Calmette-Guérin for the treatment of non-muscle-invasive transitional cell carcinoma of the bladder: new insights. Eur Urol 2012 0.75
26 Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56. Eur Urol 2009 0.75
27 High surgical volume, high quality, and low costs: a perfect combination. Is it always possible in patients who need radical prostatectomy? Eur Urol 2006 0.75
28 Phase II study of biweekly gemcitabine as first line therapy in CIS of the bladder: what does an aborted trial tell us? Urol Oncol 2011 0.75
29 5A prospective survey of current prostate biopsy practices among oncological urologists. Can J Urol 2010 0.75